CODE Chemotherapy with or without Recombinant Human Granulocyte Colony-Stimulating Factor in Extensive-Stage Small Cell Lung Cancer

Publisher Website
Google Scholar
Abstract
CODE therapy demonstrated high antitumor activity in extensive-stage small cell lung cancer (SCLC). Toxicity was acceptable in a regimen with a nine-cycle schedule. The results obtained in this study suggest that CODE therapy improves the outcome of patients with extensive-stage SCLC. The use of recombinant human granulocyte colony-stimulating factor may well reduce the duration and degree of neutropenia during CODE chemotherapy and increase the dose intensity, leading to further improvement of outcome.

This publication has 0 references indexed in Scilit: